Research programme: Tribody antibody drug conjugates - Biotecnol/PolyTherics
Latest Information Update: 16 Jul 2016
At a glance
- Originator Biotecnol Inc.; PolyTherics
- Class Antibodies; Drug conjugates
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA
- 23 Oct 2012 Early research in Cancer in USA (unspecified route)